Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world neoadjuvant sintilimab plus chemotherapy in non-small cell lung cancer
ChiCTR2200062304Phase 4Recruiting
- Sponsor
- Zunyi Medical University Affiliated Hospital
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Zunyi Medical University Affiliated Hospital. Primary endpoints: Pathological complete remission rate, Objective response rate and 1 more. Started Jul 2019; status: recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200062304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062304.